Clinical efficacy of micronized purified flavonoid fraction (MPFF) in edema

Angiology

Volumn 51, Issue 1, 2000, Pages 25-29

  Olszewski, W ^a  

^a POLISH ACADEMY OF SCIENCES   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

DAFLON; DOCETAXEL;

ADULT; CAPILLARY PERMEABILITY; CHRONIC VEIN INSUFFICIENCY; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CLASSIFICATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDICATION; FEMALE; HUMAN; LEG EDEMA; LYMPHEDEMA; MAJOR CLINICAL STUDY; MALE; MASTECTOMY; RANDOMIZED CONTROLLED TRIAL;

EID: 0033955201     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/000331970005100106     Document Type: Conference Paper

References (6)

1. Laurent R, Gilly R, Frileux C: Clinical evaluation of a venotropic drug in man. Example of Daflon 500 mg. Int Angiol 7 (suppl to no. 2):39-43, 1988.
2. Menyhei G, Acsady G, Hetenyi A, et al: Chronobiology and clinical activity of Daflon 500 mg in chronic venous insufficiency. Phlebology 9 (suppl 1):15-18, 1994.
3. Blume J, Langenbahn H, de Champvallins M: Quantification of edema using the volometer technique: Therapeutic application of Daflon 500 mg in chronic venous insufficiency. Phlebology 7 (suppl 2):37-40, 1992.
4. Pecking AP, Février B, Wargon C, et al: Efficacy of Daflon 500 mg in the treatment of lymphedema (secondary to conventional therapy of breast cancer). Angiology 48:93-98, 1997.
5. Behar A, Lagrue G, Cohen-Boulakia F, et al: Capillary filtration in idiopathic cyclic edema - effects of Daflon 500 mg. Nukl Med 27:105-107, 1988.
6. Béhar A, Pujade-Lauraine E, Maurel A, et al: The pathophysiological mechanism of fluid retention in advanced cancer patients treated with docetaxel, but not receiving corticosteroid comedication. Br J Clin Pharmacol 43:653-658, 1997.